局部皮肤黑色素瘤转移复发时间事件预测模型的开发与验证
远处复发患者生存显著更差(HR 6.21,P<.001)。梯度提升生存模型外部验证表现最佳(一致性指数0.816;时间依赖AUC 0.842;Brier评分0.103)。
要点
- 时间事件机器学习模型可预测局部黑色素瘤的转移复发。
- 梯度提升生存模型外部验证一致性指数达0.816。
- 远处复发患者死亡风险显著高于局部/无复发者(HR 6.21)。
核心结论
- 时间事件机器学习模型能可靠预测局部黑色素瘤的转移复发,有助于识别最可能从免疫治疗中获益的高危患者。
研究设计与样本
- 回顾性队列研究,纳入2000至2020年Mass General Brigham和Dana-Farber癌症研究所诊断的I/II期原发性皮肤黑色素瘤患者,共954例黑色素瘤(155例远处复发、163例局部复发、636例1:2匹配无复发)。
主要发现
- 远处复发患者生存显著差于局部复发/无复发者(HR 6.21,P<.001)。
- 远处复发患者生存显著差于仅局部复发者(HR 5.79,P<.001)。
- 梯度提升生存模型外部验证表现最佳:一致性指数0.816,时间依赖AUC 0.842,Brier评分0.103。
临床怎么用
- 模型可用于识别局部黑色素瘤高转移复发风险患者,辅助筛选免疫治疗候选者。
局限性
- 研究为回顾性设计。
- 队列来自单一地理区域。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recent expansion of immunotherapy for stage IIB/IIC melanoma highlights a growing clinical need to identify patients at high risk of metastatic recurrence and, therefore, most likely to benefit from this therapeutic modality. OBJECTIVE: To develop time-to-event risk prediction models for melanoma metastatic recurrence. METHODS: Patients diagnosed with stage I/II primary cutaneous melanoma between 2000 and 2020 at Mass General Brigham and Dana-Farber Cancer Institute were included. Melanoma recurrence date and type were determined by chart review. Thirty clinicopathologic factors were extracted from electronic health records. Three types of time-to-event machine-learning models were evaluated internally and externally in the distant versus locoregional/nonrecurrence prediction. RESULTS: This study included 954 melanomas (155 distant, 163 locoregional, and 636 1:2 matched nonrecurrences). Distant recurrences were associated with worse survival compared to locoregional/nonrecurrences (HR: 6.21, P < .001) and to locoregional recurrences only (HR: 5.79, P < .001). The Gradient Boosting Survival model achieved the best performance (concordance index: 0.816; time-dependent AUC: 0.842; Brier score: 0.103) in the external validation. LIMITATIONS: Retrospective nature and cohort from one geography. CONCLUSIONS: These results suggest that time-to-event machine-learning models can reliably predict the metastatic recurrence from localized melanoma and help identify high-risk patients who are most likely to benefit from immunotherapy.
引用
- Wan G, Leung BW, DeSimone MS, et al. Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma. J Am Acad Dermatol. 2023. PMID: 37797836. doi:10.1016/j.jaad.2023.08.105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。